From Farm to Pharmacy

NEW WHITE PAPER

Building Traceability and Transparency in the Pharmaceutical Supply Chain

Where Pharmaceutical Supply Chains Actually Break

Most companies can trace to the API supplier.
Few can trace to precursor or feedstock origin.

As pharmaceutical supply chains grow more complex, visibility beyond direct suppliers is essential. In this white paper in collaboration with BioAktive, we present a tiered framework to help organisations map upstream suppliers, strengthen compliance, and proactively manage risk. Discover how greater transparency can improve resilience, protect product integrity, and create long-term strategic advantage.

Tier 1 compliance is not full transparency.

Supplier documentation does not equal upstream visibility

Traders and subcontracting create structural blind spots

Tier 2 and Tier 3 concentration risk is often undisclosed

ESG and regulatory expectations are increasing

— What you’ll learn —

  • The Tier 1–3 Traceability Framework

  • A Paracetamol supply chain case study

  • Where documentation fails to equal real traceability

  • How to identify upstream exposure

  • A practical roadmap for implementation

— Who this is for —

  • Procurement leaders

  • Supply chain directors

  • QA / regulatory professionals

  • ESG and compliance teams

  • Pharma and specialty chemical manufacturers

— Download & read here —